^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Anal Carcinoma

    22h
    TG4001.12: Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers (clinicaltrials.gov)
    P1/2, N=143, Active, not recruiting, Transgene | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Bavencio (avelumab) • tipapkinogene sovacivec (TG4001)
    3d
    Adaptive Radiation in Anal Cancer (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, Columbia University | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    5-fluorouracil • capecitabine • mitomycin
    4d
    ULACNet102: CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, University of California, San Francisco | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    |
    CD4 (CD4 Molecule)
    6d
    Ganglion Impar Neurolysis for the Improvement of Radiation-Induced Pain During Localized Anal or Perianal Skin Cancer Treatment (clinicaltrials.gov)
    P=N/A, N=5, Recruiting, Emory University | Not yet recruiting --> Recruiting
    Enrollment open
    10d
    RC09-FIAS: The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-preserving Surgery (clinicaltrials.gov)
    P=N/A, N=498, Not yet recruiting, The First Hospital of Jilin University
    New trial
    11d
    Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer (clinicaltrials.gov)
    P1/2, N=24, Active, not recruiting, University of Nebraska | Trial primary completion date: Dec 2025 --> Jul 2026
    Trial primary completion date
    |
    5-fluorouracil • mitomycin • BMX-001
    11d
    Dynamics of anal HPV infection after 9vHPV vaccination in men who have sex with men (MSM) with HIV: A prospective, controlled cohort study. (PubMed, Hum Vaccin Immunother)
    No significant differences were observed in anal dysplasia regression or anal microbiota composition over 12 months. Given the lack of short-term secondary benefit and persistence of HPV incidence, MSM with HIV require continued routine anal cancer screening.
    Journal
    |
    CD4 (CD4 Molecule)
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    15d
    Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2029 --> Sep 2031 | Trial primary completion date: Sep 2029 --> Sep 2031
    Trial completion date • Trial primary completion date
    |
    IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • capecitabine • Jelmyto (mitomycin urothelial gel) • fluorouracil topical • ABP 206 (nivolumab biosimilar)
    22d
    Comprehensive Genomic Profiling of Advanced Anal Adenocarcinoma in Japan. (PubMed, JCO Precis Oncol)
    Advanced anal AD exhibited a distinct genomic profile compared with advanced rectal AD. CGP is a useful approach for identifying druggable GAs in advanced anal AD to expand therapeutic opportunities.
    Retrospective data • Journal • Tumor mutational burden • BRCA Biomarker • MSi-H Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • APC (APC Regulator Of WNT Signaling Pathway)
    |
    BRAF V600E • TMB-H • MSI-H/dMMR
    24d
    Metastatic Syringocystadenocarcinoma Papilliferum Treated with Enzalutamide: A Case Report and a Review of the Literature. (PubMed, Case Rep Dermatol)
    Herein, it is described the case of a 70-year-old man affected by metastatic SCACP, treated with three different sequential therapy lines: carboplatin plus paclitaxel, epirubicin, and an off-label protocol with enzalutamide, achieving 41 months overall survival. Interestingly, SCACP demonstrated to be responsive to enzalutamide treatment, even though the patient precociously stopped the treatment due to severe toxicity. This case represents the first evidence of hormonotherapy administration in a SCACP patient, possibly providing the base for a new therapeutic opportunity for this rare malignancy.
    Journal
    |
    AR (Androgen receptor) • PRG4 (Proteoglycan 4)
    |
    carboplatin • paclitaxel • Xtandi (enzalutamide) • epirubicin
    28d
    CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial. (PubMed, BMJ Open)
    The final results will be published in a peer-reviewed journal upon completion of the study. NCT05640609.
    Clinical protocol • P1/2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Tyvyt (sintilimab) • capecitabine • oxaliplatin • Byvasda (bevacizumab biosimilar)
    29d
    MASST: Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy (clinicaltrials.gov)
    P=N/A, N=39, Active, not recruiting, University Health Network, Toronto | Trial completion date: Jul 2026 --> Jan 2027 | Trial primary completion date: Jul 2026 --> Jan 2027
    Trial completion date • Trial primary completion date